Brean Murray Adds Achillion (ACHN), Pitney Bowes (PBI), Vivus (VVUS) to 'Focus List'; Removes Gilead (GILD)

Analysts at Brean Murray Carret & Co. announced several additions to the firm's "Focus List" Monday morning. The firm is expecting near-term upside in the following stocks:

• Achillion Pharma (Nasdaq: ACHN) - Cited "shifting competitive landscape that makes Achillion's assets unique and substantially more valuable."
  
• Pitney Bowes (NYSE: PBI) - Cited "favorable risk-reward after recent retracement."
  
• Vivus (Nasdaq: VVUS) - Cited "expected approval of obesity drug."

Brean Murray removed shares of Gilead (Nasdaq: GILD) from the firm's "Focus List."

Shares of Achillion and Pitney Bowes have not yet moved on the additions, however, shares of Vivus are up 3.3 percent to $23.10 in pre-market action Monday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
• HubSpot Inc (HUBS) PT Raised to $770 at BofA Securities
• HashiCorp Inc (HCP) PT Raised to $32 at BofA Securities